Literature DB >> 16156296

Assessment of heparin binding to the AN69 ST hemodialysis membrane: I. Preclinical studies.

Jacques Chanard1, Sylvie Lavaud, Bruno Paris, Fatouma Toure, Philippe Rieu, Jean-Louis Renaux, Michel Thomas.   

Abstract

The AN69 ST membrane was designed to render the surface of the native polyacrylonitrile polymer less cationic. This was achieved by layering the membrane with the polycationic biopolymer polyethyleneimine. This new membrane is able to bind heparin to its surface, through electrical interactions, without altering the reactivity of the sulfonate groups of the membrane, regularly distributed in the membrane bulk. The kinetics of unfractionated or low-molecular-weight heparins were studied in vitro and in vivo in sheep. Encouraging results were obtained indicating that heparin-coated hemodialyzers are potent anticoagulants. Priming the AN69 ST membrane-equipped hemodialyzer with heparin, as in regular hemodialysis, could allow drastic reduction of heparin consumption in hemodialysis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16156296     DOI: 10.1097/01.mat.0000169119.06419.ed

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  9 in total

1.  Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation?

Authors:  Miet Schetz; Sophie Van Cromphaut; Jasperina Dubois; Greet Van den Berghe
Journal:  Intensive Care Med       Date:  2012-07-07       Impact factor: 17.440

2.  Surface modification of polysulfone based hemodialysis membranes with layer by layer self assembly of polyethyleneimine/alginate-heparin: a simple polyelectrolyte blend approach for heparin immobilization.

Authors:  Filiz Yasar Mahlicli; Sacide Alsoy Altinkaya
Journal:  J Mater Sci Mater Med       Date:  2013-02       Impact factor: 3.896

3.  Avoidance of systemic anticoagulation during intermittent haemodialysis with heparin-grafted polyacrilonitrile membrane and citrate-enriched dialysate: a retrospective cohort study.

Authors:  Karlien François; Karl Martin Wissing; Rita Jacobs; Dries Boone; Kristine Jacobs; Christian Tielemans
Journal:  BMC Nephrol       Date:  2014-07-03       Impact factor: 2.388

4.  Polyethyleneimine-treated polyacrylonitrile membrane hemofilter for critically ill patients receiving anticoagulant-free prolonged intermittent renal replacement therapy: a single-center, prospective, self-controlled pilot study.

Authors:  Tao Su; Qizhuang Jin; Zhongyuan Liu
Journal:  BMC Nephrol       Date:  2017-06-30       Impact factor: 2.388

5.  How biocompatible haemodialysers can conquer the need for systemic anticoagulation even in post-dilution haemodiafiltration: a cross-over study.

Authors:  Floris Vanommeslaeghe; Iván Josipovic; Matthieu Boone; Arjan van der Tol; Annemie Dhondt; Wim Van Biesen; Sunny Eloot
Journal:  Clin Kidney J       Date:  2020-12-08

Review 6.  Biocompatibility of Surface-Modified Membranes for Chronic Hemodialysis Therapy.

Authors:  Mario Bonomini; Luca Piscitani; Lorenzo Di Liberato; Vittorio Sirolli
Journal:  Biomedicines       Date:  2022-04-03

7.  Hemodialysis without systemic anticoagulation: a prospective randomized trial to evaluate 3 strategies in patients at risk of bleeding.

Authors:  Bruno Guéry; Corinne Alberti; Aude Servais; Elarbi Harrami; Lynda Bererhi; Brigitte Zins; Malik Touam; Dominique Joly
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

8.  AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective study.

Authors:  Takahiro Hirayama; Nobuyuki Nosaka; Yasumasa Okawa; Soichiro Ushio; Yoshihisa Kitamura; Toshiaki Sendo; Toyomu Ugawa; Atsunori Nakao
Journal:  J Intensive Care       Date:  2017-07-18

9.  Evaluation of Different Dialyzers and the Impact of Predialysis Albumin Priming in Intermittent Hemodialysis With Reduced Anticoagulation.

Authors:  Floris Vanommeslaeghe; Filip De Somer; Iván Josipovic; Matthieu Boone; Wim Van Biesen; Sunny Eloot
Journal:  Kidney Int Rep       Date:  2019-07-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.